SI-BONE Inc 2025年季度报告

(Mark one)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember 30, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from __________ to __________ Commission File Number:001-38701 SI-BONE,INC.(Exact Name of Registrant as Specified in its Charter) 471 El Camino Real,Suite 101,Santa Clara,California(Address of principal executive offices) Registrant's telephone number, including area code:(408)207-0700 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90days.YesxNoo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes xNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of theExchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section7(a)(2)(B) of the Securities Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐Nox The number of shares outstanding of the registrant’s Common Stock was43,391,254as of November4, 2025. TABLE OF CONTENTS PART I-FINANCIAL INFORMATION Item 1.Financial StatementsCondensed Consolidated Balance Sheets(Unaudited)Condensed Consolidated Statements of Operations and Comprehensive Loss(Unaudited)Condensed Consolidated Statements of Changes in Stockholders' Equity(Unaudited)Condensed Consolidated Statements of Cash Flows(Unaudited)Notes to Condensed Consolidated Financial Statements(Unaudited)Item 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II-OTHER INFORMATION Item 1.Legal ProceedingsItem1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits SIGNATURES SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form10-Q contains forward-looking statements. All statements other than statements of historicalfacts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, businessstrategy, prospective products and product candidates, sales force expansion, physician adoption, reimbursement determinations,clinical trial results, government shutdown, and U.S. Food and Drug Administration ("FDA") approvals, are forward-lookingstatements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results,performance or achievements to be materially different from any future results, performance or achievements expressed or implied bythe forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,”“anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or thenegative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words.These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertaintiesand assumptions, including those described under the sections in this Quarterly Report titled “Risk Factors” and “Management’sDiscussion and Analysis of Financial Condition and Results of Operations.” These forward-looking statements include, but are notlimited to, statements about the following: •our expectation that a significant portion of our revenue will be derived from sales of similar products addressing thesacropelvic anatomy;•our ability to develop and commercialize additional revenue opportunities, including new indications for use and newproducts;•our ability to retain and grow our sales team, including our third-party sales agents,